Form 8-K - Current report:
SEC Accession No. 0000950170-24-131919
Filing Date
2024-11-29
Accepted
2024-11-29 17:14:28
Documents
11
Period of Report
2024-11-26
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K virx-20241126.htm   iXBRL 8-K 41409
  Complete submission text file 0000950170-24-131919.txt   152163

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT virx-20241126.xsd EX-101.SCH 23863
14 EXTRACTED XBRL INSTANCE DOCUMENT virx-20241126_htm.xml XML 4543
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

EIN.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 241516961
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)